Table 1.
Baseline and general characteristics of the participants.
| Variables | Nonobese Control | Nonobese CRC | Overweight/Obese Control | Overweight/Obese CRC |
|---|---|---|---|---|
| N | 53 | 27 | 81 | 58 |
| Male/female, sex (%) | 22/31 (41.5/48.5) |
19/8 (70.40/29.60) a |
36/45 (44.4/55.6) |
42/16 (72.40/27.60) b |
| Age (years) | 47.94 ± 13.63 | 66.7 ± 12.98 a | 54.78 ± 14.43 | 68.22 ± 9.27 b |
| Weight (kg) | 65.30 ± 9.58 | 65.43 ± 7.93 | 78.39 ± 12.34 | 78.19 ± 11.49 |
| Waist (cm) | 83.04 ± 9.20 | 87.57 ± 11.27 | 99.86 ± 10.95 | 101.84 ± 12.72 |
| BMI (kg/m2) | 22.97 ± 1.73 | 23.19 ± 1.61 | 30.02 ± 3.59 | 29.09 ± 3.34 |
| Glucose (mg/dL) | 91.97 ± 14.14 | 133.35 ± 79.53 | 108.08 ± 28.13 | 119.36 ± 38.86 |
| Insulin (µIU/mL) | 7.30 ± 5.47 | 9.01 ± 6.12 a | 10.5 ± 5.68 | 7.30 ± 0.95 b |
| Hb1Ac (%) | 5.56 ± 0.52 | 5.78 ± 0.84 | 5.84 ± 1.23 | 5.93 ± 0.95 |
| HOMA-IR | 2.11 ± 1.66 | 1.36 ± 1.28 | 1.98 ± 1.26 | 1.08 ± 1.26 |
| Cholesterol (mg/dL) | 197.92 ± 29.94 | 178.54 ± 45.76 | 211.89 ± 39.89 | 170.43 ± 38.89 b |
| Triglycerides(mg/dL) | 108.14 ± 72.45 | 142.69 ± 74.62 | 131.90 ± 54.35 | 170.00 ± 79.35 b |
| HDL (mg/dL) | 54.84 ± 14.46 | 43.77 ± 14.04 a | 53.94 ± 12.77 | 40.34 ± 13.83 b |
| LDL (mg/dL) | 122.39 ± 24.58 | 108.41 ± 35.68 | 132.54 ± 32.31 | 101.07 ± 32.31 b |
| Alkaline phosphatase (U/L) | 62.06 ± 25.79 | 63.62 ± 24.69 | 71.70 ± 19.92 | 71.97 ± 29.63 |
Results are presented as means ± SD. a Significant difference between nonobese (BMI < 25 kg/m2) control and nonobese CRC; b Significant difference between overweight/obese (BMI ≥ 25 kg/m2) control and overweight/obese CRC patients according Wilcoxon test and Chi squared test for gender variables expressed as percentage (p < 0.05). Abbreviations: CRC: Colorectal cancer; BMI: Body Mass Index; HbA1c: Glycated hemoglobin; HOMA-IR: Homeostasis model assessment of insulin resistance; HDL: High density lipoprotein; LDL: Low density lipoprotein.